CA1338078C - Partial cationization of protein-containing antigens and method of immunization and desensitization - Google Patents
Partial cationization of protein-containing antigens and method of immunization and desensitizationInfo
- Publication number
- CA1338078C CA1338078C CA000557550A CA557550A CA1338078C CA 1338078 C CA1338078 C CA 1338078C CA 000557550 A CA000557550 A CA 000557550A CA 557550 A CA557550 A CA 557550A CA 1338078 C CA1338078 C CA 1338078C
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- protein
- cationized
- partially cationized
- containing substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 35
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 35
- 239000000427 antigen Substances 0.000 title claims description 44
- 108091007433 antigens Proteins 0.000 title claims description 44
- 102000036639 antigens Human genes 0.000 title claims description 44
- 238000000034 method Methods 0.000 title abstract description 39
- 230000003053 immunization Effects 0.000 title abstract description 11
- 238000002649 immunization Methods 0.000 title abstract description 10
- 238000000586 desensitisation Methods 0.000 title abstract description 4
- 239000000126 substance Substances 0.000 claims abstract description 51
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 230000028993 immune response Effects 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 108050000784 Ferritin Proteins 0.000 claims description 6
- 102000008857 Ferritin Human genes 0.000 claims description 6
- 238000008416 Ferritin Methods 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 229960000814 tetanus toxoid Drugs 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 5
- 229940098773 bovine serum albumin Drugs 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- 239000002158 endotoxin Substances 0.000 claims description 4
- 150000003141 primary amines Chemical class 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 108010058846 Ovalbumin Proteins 0.000 claims description 3
- 108010074605 gamma-Globulins Proteins 0.000 claims description 3
- 238000001155 isoelectric focusing Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 150000003512 tertiary amines Chemical class 0.000 claims description 3
- 230000006806 disease prevention Effects 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 2
- 108010067390 Viral Proteins Proteins 0.000 claims 2
- 244000005700 microbiome Species 0.000 claims 2
- 150000003335 secondary amines Chemical class 0.000 claims 2
- -1 tetanus toxoid Proteins 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 229920002401 polyacrylamide Polymers 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 abstract description 10
- 230000001965 increasing effect Effects 0.000 abstract description 8
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 230000004044 response Effects 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 11
- 229940037003 alum Drugs 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000008351 acetate buffer Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 108010062573 polycationic ferritin Proteins 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004043 responsiveness Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241001163743 Perlodes Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000009851 immunogenic response Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- AOMZHDJXSYHPKS-DROYEMJCSA-L Amido Black 10B Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC2=CC(S([O-])(=O)=O)=C(\N=N\C=3C=CC=CC=3)C(O)=C2C(N)=C1\N=N\C1=CC=C(N(=O)=O)C=C1 AOMZHDJXSYHPKS-DROYEMJCSA-L 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 101100508407 Caenorhabditis elegans mua-6 gene Proteins 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ZIJKGAXBCRWEOL-SAXBRCJISA-N Sucrose octaacetate Chemical compound CC(=O)O[C@H]1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1 ZIJKGAXBCRWEOL-SAXBRCJISA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 239000001344 [(2S,3S,4R,5R)-4-acetyloxy-2,5-bis(acetyloxymethyl)-2-[(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxolan-3-yl] acetate Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002096 anti-tetanic effect Effects 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AOMZHDJXSYHPKS-UHFFFAOYSA-L disodium 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC2=CC(S([O-])(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 AOMZHDJXSYHPKS-UHFFFAOYSA-L 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 108010006205 fluorescein isothiocyanate bovine serum albumin Proteins 0.000 description 1
- 108010031559 fluorescein isothiocyanate-keyhole limpet hemocyanin Proteins 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229940099076 maalox Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940013883 sucrose octaacetate Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US923487A | 1987-01-30 | 1987-01-30 | |
| US07/009,234 | 1987-01-30 | ||
| US14706388A | 1988-01-22 | 1988-01-22 | |
| USCIP07/147,063 | 1988-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1338078C true CA1338078C (en) | 1996-02-20 |
Family
ID=26679235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000557550A Expired - Fee Related CA1338078C (en) | 1987-01-30 | 1988-01-28 | Partial cationization of protein-containing antigens and method of immunization and desensitization |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0300007A1 (de) |
| JP (1) | JPH01502024A (de) |
| KR (1) | KR890700355A (de) |
| AU (1) | AU618946B2 (de) |
| CA (1) | CA1338078C (de) |
| IL (1) | IL85256A (de) |
| WO (1) | WO1988005664A1 (de) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7323171B2 (en) | 1991-10-07 | 2008-01-29 | Astellas Us Llc | Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US7662921B2 (en) | 2004-05-07 | 2010-02-16 | Astellas Us Llc | Methods of treating viral disorders |
| US7858095B2 (en) | 2001-07-24 | 2010-12-28 | Astellas Us Llc | Method for treating or preventing sclerotic disorders using CD-2 binding agents |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2233925A1 (de) | 2009-03-26 | 2010-09-29 | Corning Inc. | Immobilisierungsverfahren für Protein mit niedrigem isoelektrischem Punkt |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3825525A (en) * | 1969-08-06 | 1974-07-23 | Beecham Group Ltd | Allergens reacted with carbodiimides |
| US3761585A (en) * | 1971-04-05 | 1973-09-25 | Beecham Group Ltd | Vaccines containing modified allergenic material |
-
1988
- 1988-01-25 EP EP88901145A patent/EP0300007A1/de not_active Withdrawn
- 1988-01-25 AU AU11836/88A patent/AU618946B2/en not_active Ceased
- 1988-01-25 WO PCT/US1988/000196 patent/WO1988005664A1/en not_active Ceased
- 1988-01-25 JP JP63501361A patent/JPH01502024A/ja active Pending
- 1988-01-28 CA CA000557550A patent/CA1338078C/en not_active Expired - Fee Related
- 1988-01-29 IL IL85256A patent/IL85256A/xx not_active IP Right Cessation
- 1988-09-30 KR KR1019880701217A patent/KR890700355A/ko not_active Ceased
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7323171B2 (en) | 1991-10-07 | 2008-01-29 | Astellas Us Llc | Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction |
| US7858095B2 (en) | 2001-07-24 | 2010-12-28 | Astellas Us Llc | Method for treating or preventing sclerotic disorders using CD-2 binding agents |
| US7662921B2 (en) | 2004-05-07 | 2010-02-16 | Astellas Us Llc | Methods of treating viral disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| IL85256A (en) | 1993-08-18 |
| WO1988005664A1 (en) | 1988-08-11 |
| IL85256A0 (en) | 1988-07-31 |
| AU618946B2 (en) | 1992-01-16 |
| AU1183688A (en) | 1988-08-24 |
| JPH01502024A (ja) | 1989-07-13 |
| EP0300007A1 (de) | 1989-01-25 |
| KR890700355A (ko) | 1989-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5955079A (en) | Dual carrier immunogenic construct | |
| JP2921574B2 (ja) | 接合体ワクチンの担体分子としてのｔ細胞のエピトープ | |
| US6350449B1 (en) | Antibodies to meningococcal polysaccharide conjugate vaccines | |
| EP0549617B1 (de) | Verbesserte vakzinzusammensetzung | |
| EP0720485B1 (de) | Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten | |
| AU740784B2 (en) | Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines | |
| JPH08500102A (ja) | 免疫原性に乏しい抗原と合成ペプチド担体との結合体およびそれらからなるワクチン | |
| JP2010500354A (ja) | タンパク質マトリックスワクチンおよびそのようなワクチンの製造方法および投与方法 | |
| EP0789590B1 (de) | Chitosan induzierte verstärkung | |
| CA1338078C (en) | Partial cationization of protein-containing antigens and method of immunization and desensitization | |
| Naor et al. | Immune response to chemically modified antigens | |
| US5110794A (en) | Method of immunization with partially cationized substances and said partially cationized substances | |
| CZ296577B6 (cs) | Polymer a jeho pouzití ke stimulaci imunitní odpovedi | |
| RU2021817C1 (ru) | Способ получения вакцины против холеры | |
| WO1993015758A1 (en) | Composition and method of immunization with improved carrier and hapten-carrier vaccines | |
| US20020127232A1 (en) | Immune response modulator alpha-2 macroglobulin complex | |
| EP0646377A1 (de) | Albumin-konjugierte zellfreie Tumorextrakte, diese enthaltende antigene Zusammensetzungen, entsprechende Antikörper und Verwendungen | |
| JP2000504350A (ja) | キトサン誘導性免疫強化 | |
| EP0776216A1 (de) | Dualer traeger fuer immunogene konstrukte |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |